Dynamics of peritoneal transport and cardiovascular outcomes of peritoneal dialysis treatment DOI Open Access
Karina Salikhova, Роман Герасимчук, Anastasia Sabodash

et al.

HERALD of North-Western State Medical University named after I I Mechnikov, Journal Year: 2024, Volume and Issue: 16(3), P. 44 - 59

Published: Nov. 6, 2024

BACKGROUND: Solute and water transport by peritoneal membrane has significant variation between patients; the function changes significantly over time. This affects treatment outcomes requires individual approaches. AIM: To evaluate influence of baseline state, its dynamics during dialysis possibility long-term modification. MATERIALS AND METHODS: The solutes (in equilibrium test, PET) mini-PET) was evaluated in a prospective interventional open-label study with historical control among 96 unselected consecutive patients admitted three centers unified program monitoring protection. RESULTS: Compared to matched standard arm, increase solute slower (by 9.5%) observation group. Ultrafiltration classical PET decreased more slowly 28%). At ultrafiltration satisfactory (the proportion less 400 ml 7.6%); small pores did not decrease (−1.1 ± 5.9 ml/year), total 32.1 8.2 ml/year) due free 29.9 7.6 ml/year). Negative associated glucose load monthly greater than 2.68 kg/month. More one case peritonitis rapid decline transport. comorbidity increased 34 patients, median first/last scores 5 (4–6) 6 (4–7) points; (Wilcoxon Z = −5.423; p 0.001). When analyzed separately category, worsening index observed only for high average transporters (Z −2.754, 0.006 −3.357, 0.001, respectively). CONCLUSIONS: interaction transport, primarily cardiovascular disease is certainly two-way: deterioration balance loss effective leads volume overload progression disease. On other hand, contributes damage. most sensitive interventions effectiveness protection preventing separate measuring through ultrapores, which simultaneously reveals feature progressive fibrosis, potential precursor encapsulating sclerosis.

Language: Английский

Dyslipidemia in Peritoneal Dialysis: Implications for Peritoneal Membrane Function and Patient Outcomes DOI Creative Commons
N. Stepanova

Biomedicines, Journal Year: 2024, Volume and Issue: 12(10), P. 2377 - 2377

Published: Oct. 17, 2024

Dyslipidemia is a common metabolic complication in patients undergoing peritoneal dialysis (PD) and has traditionally been viewed primarily terms of cardiovascular risk. Current guidelines do not recommend initiating lipid-lowering therapy due to insufficient evidence its benefits on mortality. However, the impact dyslipidemia PD may extend beyond concerns, influencing PD-related outcomes such as ultrafiltration rate, residual kidney function, technique survival, overall This review challenges traditional perspective by discussing dyslipidemia’s potential role complications, which account for observed link between increased all-cause mortality patients. It explores pathophysiology PD, molecular mechanisms linking membrane dysfunction, summarizes clinical supporting this hypothesis. In addition, paper examines therapeutic strategies manage improve function patient outcomes. The calls future research investigate contributor dysfunction develop targeted interventions

Language: Английский

Citations

1
Mechanisms underlying the involvement of peritoneal macrophages in the pathogenesis and novel therapeutic strategies for dialysis-induced peritoneal fibrosis DOI Creative Commons

Yangwei Wang,

Yixian Zhang,

Mingqi Ma

et al.

Frontiers in Immunology, Journal Year: 2024, Volume and Issue: 15

Published: Dec. 19, 2024

Long-term exposure of the peritoneum to peritoneal dialysate results in pathophysiological changes anatomical organization and progressive development fibrosis. This leads a decline function ultrafiltration failure, ultimately necessitating discontinuation dialysis, severely limiting potential for long-term maintenance. Additionally, encapsulating sclerosis, serious consequence fibrosis, resulting patients discontinuing PD significant mortality. The causes mechanisms underlying fibrosis undergoing dialysis remain unknown, with no definitive treatment available. However, abnormal activation immune system appears be involved altering structure promoting fibrotic changes. Macrophage infiltration polarization are key contributors pathological injury within peritoneum, showing strong correlation epithelial-to-mesenchymal transition mesothelial cells driving process article discusses role macrophage activation-induced from by analyzing relevant literature past decade provides an overview recent therapeutic approaches targeting macrophages treat this condition.

Language: Английский

Citations

1
Luteolin blocks the ROS/PI3K/AKT pathway to inhibit mesothelial-mesenchymal transition and reduce abdominal adhesions DOI Creative Commons
Yiwei Ren, Li Gan, Enmeng Li

et al.

European Journal of Pharmacology, Journal Year: 2023, Volume and Issue: 964, P. 176272 - 176272

Published: Dec. 17, 2023

Postoperative abdominal adhesion (PAA) is a common postoperative complication. Clinically, various methods have been used to prevent the occurrence of PAA, such as drugs and physiotherapy; however, no satisfactory results obtained. Luteolin (LUT) natural flavonoid that reduces inflammation acts an antioxidant. This research aimed examine impact mechanism LUT in reducing PAA. C57/BL6 mice were vivo experiments. PAA model was established using brush friction method. Visual scoring hematoxylin eosin staining score severity adhesions. Network pharmacology infer potential targets core pathways LUT. Hydrogen peroxide (H2O2) induce oxidative stress vitro, while reactive oxygen species (ROS) assay kit evaluate levels. Western blotting, cell immunofluorescence, multiple immunofluorescence assays detect α-SMA, vimentin, E-cadherin, collagen I, or AKT phosphorylation level. Scratch migration. reduced degree mice. It attenuated H2O2-induced ROS production reversed mesothelial-mesenchymal transition (MMT) HMrSV5 cells. analysis showed likely exerted anti-adhesion activity by regulating PI3K-Akt signaling pathway. Phosphorylated Akt levels significantly LUT-treated also expression vimentin I adherent tissues upregulated E-cadherin expression. blocks ROS/PI3K/AKT pathway, thereby inhibiting MMT To this end, has therapy.

Language: Английский

Citations

2
Dialysate cyclophilin A as a predictive marker for historical peritonitis in patients undergoing peritoneal dialysis DOI Creative Commons

Shang‐Feng Tsai,

Cheng‐Hsu Chen,

Ming-Ju Wu

et al.

Heliyon, Journal Year: 2024, Volume and Issue: 10(10), P. e31021 - e31021

Published: May 1, 2024

No markers have been used to diagnose historical peritoneal dialysis (PD)-related peritonitis. Cyclophilin A (CypA) is associated with glucose toxicity and inflammation. We hypothesize that dialysate CypA can be a marker for peritonitis (at least 3 months free from peritonitis).

Language: Английский

Citations

0
JPH203 alleviates peritoneal fibrosis via inhibition of amino acid-mediated mTORC1 signaling DOI Creative Commons

Tiangang Wu,

Zanzhe Yu, Junhao Dai

et al.

Biochemical and Biophysical Research Communications, Journal Year: 2024, Volume and Issue: 734, P. 150656 - 150656

Published: Sept. 4, 2024

Language: Английский

Citations

0
Dynamics of peritoneal transport and cardiovascular outcomes of peritoneal dialysis treatment DOI Open Access
Karina Salikhova, Роман Герасимчук, Anastasia Sabodash

et al.

HERALD of North-Western State Medical University named after I I Mechnikov, Journal Year: 2024, Volume and Issue: 16(3), P. 44 - 59

Published: Nov. 6, 2024

BACKGROUND: Solute and water transport by peritoneal membrane has significant variation between patients; the function changes significantly over time. This affects treatment outcomes requires individual approaches. AIM: To evaluate influence of baseline state, its dynamics during dialysis possibility long-term modification. MATERIALS AND METHODS: The solutes (in equilibrium test, PET) mini-PET) was evaluated in a prospective interventional open-label study with historical control among 96 unselected consecutive patients admitted three centers unified program monitoring protection. RESULTS: Compared to matched standard arm, increase solute slower (by 9.5%) observation group. Ultrafiltration classical PET decreased more slowly 28%). At ultrafiltration satisfactory (the proportion less 400 ml 7.6%); small pores did not decrease (−1.1 ± 5.9 ml/year), total 32.1 8.2 ml/year) due free 29.9 7.6 ml/year). Negative associated glucose load monthly greater than 2.68 kg/month. More one case peritonitis rapid decline transport. comorbidity increased 34 patients, median first/last scores 5 (4–6) 6 (4–7) points; (Wilcoxon Z = −5.423; p 0.001). When analyzed separately category, worsening index observed only for high average transporters (Z −2.754, 0.006 −3.357, 0.001, respectively). CONCLUSIONS: interaction transport, primarily cardiovascular disease is certainly two-way: deterioration balance loss effective leads volume overload progression disease. On other hand, contributes damage. most sensitive interventions effectiveness protection preventing separate measuring through ultrapores, which simultaneously reveals feature progressive fibrosis, potential precursor encapsulating sclerosis.

Language: Английский

Citations

0